Subcutaneous Fat Accumulation and Thiazolidinedione Derivatives : Sex Differences and Their Relation to Glycemic Control
Year: 2003
Type: article
Study design: Clinical Trial
Abstract: We investigated changes in body fat distribution during long-term treatment with troglitazone and its effect on glycemic control.We administered troglitazone at 400 mg/day to 40 outpatients with type 2 diabetes.Twenty-one drug-naive patients (8 men and 13 women)received troglitazone monotherapy for 16 months, and 19 patients (10 men and 9 women) who had been receiving glibenclamide continued this drug and also received troglitazone for 16 months.Levels of glycosylated hemoglobin significantly decreased and body mass index significantly increased in the men and women receiving troglitazone alone and in women receiving both glibenclamide and troglitazone.No significant changes were observed in the area of visceral fat in any treatment group.A significant increase in subcutaneous fat was observed in the men and women receiving troglitazone alone and in women receiving both glibenclamide and troglitazone.Although no sex difference was observed in the percentages of patients with reduced levels of gycosylated hemoglobin or increased subcutaneous fat among those receiving troglitazone, a significantly higher percentage of women had these changes among patients receiving both glibenclamide and troglitazone.The apparent sex difference in the degree of glycemic control produced by thiazolidinedione therapy in our subjects can be attributed to the increase in subcutaneous fat after treatment and to a pretreatment difference in the subcutaneous fat.(Jikeikai Med J 2003; 50: 85-91)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W139903447